KRYSTAL-10 is an ongoing phase 3 trial currently investigating adagrasib with cetuximab versus standard fluoropyrimidine-based chemotherapy in second-line metastatic KRAS G12C-mutated colon cancer (NCT04793958). This evidence concerns the gene KRAS and colonic neoplasm.